GLP-1 drugs for PCOS: what 16 studies actually found

The short answer

In early trials, GLP-1 drugs such as semaglutide and liraglutide helped many women with PCOS lose meaningful weight, lower insulin resistance and get more regular periods. No GLP-1 is FDA-approved for PCOS yet, so this is off-label use, and the PCOS-specific evidence is still small, short and far from settled.

If you have PCOS and you keep seeing Ozempic and Wegovy mentioned online, you want a straight answer: do they actually help? A September 2025 scoping review in the journal Cureus pulled together the 16 studies that exist so far. The early signal on weight, insulin and periods is genuinely encouraging. The evidence behind it is thinner than the headlines suggest, and that gap matters when you are deciding what to do.

What does PCOS have to do with insulin?

Polycystic ovary syndrome (PCOS) is a common hormonal condition that changes how the ovaries work. It often shows up as irregular periods, higher male-type hormones (androgens) and stubborn weight gain. For most women with PCOS, insulin resistance sits underneath all of it.

Insulin resistance means the body has to pump out more insulin to keep blood sugar steady. That extra insulin pushes the ovaries to make more testosterone, which drives many PCOS symptoms. So anything that lowers insulin resistance can, in theory, ease the whole chain. That is exactly where GLP-1 medications come in.

GLP-1 drugs (Ozempic, Wegovy, Mounjaro and others) slow the stomach, quiet appetite and improve how the body handles insulin. Researchers are interested in PCOS because the drug targets the root problem, not just the symptoms on the surface.

Do GLP-1 drugs help with weight and insulin in PCOS?

This is where the evidence is strongest. Across the review, women on a GLP-1, often alongside metformin, lost more weight and improved their insulin markers more than women on metformin alone. A few results stand out:

Study and setup	What happened
Liraglutide + metformin (Long 2023, 102 women, 12 weeks)	Average 7.25 kg weight loss; BMI down 2.89 (both p<0.001)
Semaglutide 0.5 mg weekly (Carmina and Longo 2023, 27 women, 3 months)	21 of 27 lost at least 5% of body weight; insulin and HOMA-IR fell (p<0.01)
Liraglutide 3 mg (Elkind-Hirsch 2022, 92 women, 32 weeks)	BMI dropped from 41.6 to 39.1; HOMA-IR improved
Semaglutide, then metformin (Jensterle 2024, 25 women)	Weight fell from 101 kg to 92 kg, and stayed near 95 kg two years later on metformin

The pattern is consistent: lower weight, lower fasting insulin and better insulin sensitivity. In the Carmina and Longo study, up to 80% of women returned to normal fasting glucose. These are the metabolic wins PCOS care has chased for years.

Exenatide, an older GLP-1 drug, added another data point. In a trial of 153 women with prediabetes and PCOS (Tao 2021), prediabetes went into remission more often with exenatide alone (p=0.003) and with exenatide plus metformin (p=0.027) than with metformin alone.

Can they make your periods and hormones more regular?

Here the evidence is promising but smaller. In one trial (Xing 2022, 52 women, 12 weeks), menstrual cycles recovered in 88% of women on liraglutide plus metformin, versus 52% on metformin alone.

Testosterone also moved in the right direction. In a semaglutide study (Jensterle 2024), testosterone fell from 6.16 ng/dL to 4.12 ng/dL (p=0.012) and had not rebounded two years later. Other studies saw drops in testosterone, androstenedione and the free androgen index.

One honest caveat: researchers still cannot say whether better periods and lower androgens come from the weight loss itself or from the improvement in insulin. Early findings suggest both play a part, but the mechanism is not pinned down.

What the research still cannot tell you

The Cureus review is careful about its own limits, and so should you be. The studies behind these numbers are mostly small, short and run at a single center.

• No GLP-1 drug is FDA-approved for PCOS. Every use described here is off-label and prescriber-led.
• Most trials ran about 12 weeks. Long-term effects on PCOS are essentially unstudied.
• Fertility was not measured in a way that supports any pregnancy claim, despite how often GLP-1 and fertility get linked online.
• Tirzepatide (Mounjaro, Zepbound) and retatrutide have almost no PCOS-specific data. Their promise is extrapolated from diabetes and obesity trials.
• Weight tends to return after stopping, the same rebound seen in weight-loss use. One study kept most of it off by switching to metformin.

None of this means GLP-1 drugs do not work for PCOS. It means the confident, finished-sounding answers you see online are running ahead of what the science has actually shown.

Why nutrition matters if you take a GLP-1 for PCOS

There is a catch that rarely makes the headlines. The same appetite drop that drives weight loss also shrinks how much food, and how many nutrients, you take in. Women with PCOS already run a higher risk of low vitamin D, and anyone eating far less can fall short on protein, vitamin B12, iron and magnesium.

GLP-1 side effects like nausea make this worse by cutting intake further in the early weeks. Losing weight while losing muscle and running low on key nutrients is not the outcome anyone wants. Protecting protein and closing nutrient gaps is part of doing this well, which is the exact problem GLP-1 Shield is built to address.

So if you are using a GLP-1 for PCOS, treat nutrition as part of the plan, not an afterthought. Ask your clinician about checking vitamin D, vitamin B12 and iron, and keep protein high enough to hold on to muscle.

Key takeaways

• In early studies, GLP-1 drugs lowered weight, insulin resistance and testosterone in women with PCOS.
• Liraglutide plus metformin restored regular periods in 88% of women in one 12-week trial, versus 52% on metformin alone.
• No GLP-1 is FDA-approved for PCOS; all current use is off-label and should be prescriber-led.
• The evidence is early: small, short trials, with fertility and long-term effects still unstudied.
• Appetite suppression can open nutrient gaps, so protein and vitamins like vitamin D and vitamin B12 matter more, not less.

Frequently asked questions

Is Ozempic approved for PCOS?

No. No GLP-1 drug, including Ozempic, Wegovy or Mounjaro, is FDA-approved specifically for PCOS. Doctors who prescribe them for PCOS do so off-label, usually to target the insulin resistance and weight gain that drive the condition. Early trials are encouraging, but approval would need larger, longer PCOS-specific studies.

Does metformin or a GLP-1 work better for PCOS?

In the studies reviewed, a GLP-1 combined with metformin usually beat metformin alone on weight, insulin and menstrual regularity. In one trial, periods returned in 88% of women on liraglutide plus metformin versus 52% on metformin alone. Metformin is still first-line and far cheaper, so the right choice depends on your situation and your prescriber.

Will a GLP-1 help me get pregnant if I have PCOS?

The current research cannot answer this. Fertility was not directly measured in the PCOS studies, so any pregnancy claim runs ahead of the evidence. GLP-1 drugs should be stopped before a planned pregnancy because their safety in pregnancy is not established. Talk to your doctor if conceiving is your goal.

Do GLP-1 drugs cure PCOS?

No. GLP-1 drugs do not cure PCOS. They appear to improve several PCOS features, including weight, insulin resistance and androgen levels, while you take them. In studies, weight and symptoms tended to return after stopping, which points to ongoing management rather than a cure.